Pharma BD Deal Intelligence
A $540M ophthalmology acquisition that never delivered a marketed drug. Sanofi killed both of Fovea's clinical assets—ecallantide in 2012 and its diabetic macular edema candidate the same year—and later returned related gene-therapy rights to Oxford Biomedica in 2019-2020 after a portfolio review.
Sanofi's $540M ophthalmology bet never produced a marketed drug — both of Fovea's own clinical assets were killed within three years, and related gene-therapy programs were handed back a decade later.
Full analysis, sources & comparables →GEN framed the deal as defensive: "acquisition of Fovea will help the firm pad its pipeline, as it faces generic competition to its top-selling drug" (Plavix),…
Chris Viehbacher described "the very promising and dynamically growing ophthalmic area" as "a major opportunity for Sanofi"; Marc Cluzel, Sanofi's R&D chief,…
Christopher A. Viehbacher, CEO of sanofi-aventis: "FOVEA is a unique opportunity to lay the foundation stone of an ophthalmology franchise" — the deal was for…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sanofi-Aventis acquired Fovea Pharmaceuticals, a French ophthalmology-focused biotech, for a total enterprise value of up to EUR 370 million (~$540 million), comprising an upfront payment and milestone payments tied to Fovea's three clinical compounds. Announced October 1, 2009 and closed October 30, 2009, the acquisition laid the foundation of an ophthalmology franchise for Sanofi-Aventis as it faced generic pressure on Plavix. Fovea's venture backers, including Sofinnova Partners, Abingworth, the Wellcome Trust and Gimv, exited through the sale.
Sanofi's $540M ophthalmology bet never produced a marketed drug — both of Fovea's own clinical assets were killed within three years, and related gene-therapy programs were handed back a decade later.
Assessment window: 15yr post-close.
$538M Total enterprise value up to EUR 370M (~$538.7M) including upfront + milestones
Fovea Pharmaceuticals SA was a Paris-based private biotech focused exclusively on retinal and ocular surface diseases — allergic conjunctivitis, retinal vein occlusion-induced macular edema, diabetic macular edema, retinitis pigmentosa, glaucoma and dry age-related macular degeneration. These conditions affect aging populations broadly, with diabetic macular edema and AMD among the leading causes of vision loss in developed markets, and only a small number of approved therapies (Lucentis, Avastin off-label, Macugen, Ozurdex, steroid implants) at the time of the deal.
When Sanofi-Aventis acquired Fovea in 2009, the ophthalmology landscape was dominated by Genentech/Novartis's Lucentis (ranibizumab), Regeneron/Bayer's emerging Eylea (aflibercept) program (still pre-approval), Allergan's Restasis and Ozurdex steroid implant, Novartis's Visudyne, and off-label intravitreal Avastin. The Fovea deal, structured at up to EUR 370M (~$538.7M) per GEN, gave Sanofi three clinical assets — FOV 1101 (fixed-dose prednisolone+cyclosporine eye drop, Phase II for persistent allergic conjunctivitis), FOV 2302 (intravitreal plasma kallikrein inhibitor, Phase I for retinal vein occlusion-induced macular edema), and FOV 2304 (bradykinin B1 receptor antagonist, Phase I-ready for diabetic macular edema) — plus FOV 2501, an intravitreal RdCVF formulation for retinitis pigmentosa with potential extension to dry AMD. CEO Christopher A. Viehbacher said: 'FOVEA is a unique opportunity to lay the foundation stone of an ophthalmology franchise' (bionity). Marc Cluzel, then Sanofi R&D chief, framed the deal as part of pipeline diversification ahead of Plavix's 2011 patent cliff (GEN). (Forward-looking close: ten years post-close the Fovea bet had under-delivered — Sanofi quietly de-prioritized the standalone ophthalmology unit, FOV 1101 progressed only as far as Phase III before being shelved, and Sanofi's planned ophthalmology franchise never materialized as a meaningful franchise; by 2018-2019 Eylea (Regeneron/Bayer) and Lucentis biosimilars dominated the retinal space and Sanofi had effectively exited.)
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi-Aventis / Fovea Pharmaceuticals SA (this deal) | 2009 | $541M | 23 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Sanofi-Aventis / Merial Limited (Merck's 50% interest) | 2009 | $4.0B | 65 |
| Sanofi-Aventis / Acambis plc | 2008 | $548M | 36 |
| Sanofi-Aventis / Shantha Biotechnics Limited | 2009 | $784M | 34 |
| Sanofi-Aventis / BiPar Sciences, Inc. | 2009 | $500M | 8 |
| Sanofi-Aventis / ImmunoGen Inc. | 2005 | $18M | — |
← Browse all deals · How we score deals
More: 2009 deals · Sanofi-Aventis deals